スポンサーリンク
Department Of Pharmacy Faculty Of Medicine Kyoto University Hospital Kyoto University | 論文
- 成人生体肝移植症例において, ラベプラゾールの併用はタクロリムスの血中濃度推移に影響を及ぼさない
- PROTECTIVE EFFECT OF N-ACYL AMINO ACID DERIVATIVES ON CEPHALORIDINE NEPHROTOXICITY IN RABBITS
- UGT1A1^*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
- EFFECT OF CYP2C POLYMORPHISMS ON THE PHARMACOKINETICS OF PHENYTOIN IN JAPANESE PATIENTS WITH EPILEPSY
- Population Pharmacokinetics of Phenytoin in Japanese Patients with Epilepsy : Analysis with a Dose-Dependent Clearance Model
- TRANSPORT MECHANISMS OF BESTATIN IN INTESTINAL AND RENAL BRUSH-BORDER MEMBRANES
- TRANSPORT MECHANISMS OF β-LACTAM ANTIBIOTICS IN INTESTINAL BRUSH-BORDER MEMBRANES
- TRANSPORT MECHANISMS OF CATIONIC DRUGS IN RAT RENAL BRUSH-BORDER AND BASOLATERAL MEMBRANES
- TRANSPORT OF DRUGS BY PLASMA MEMBRANE VESICLES ISOLATED FROM RAT KIDNEY CORTEX
- Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney
- Distinct Effects of Omeprazole and Rabeprazole on the Tacrolimus Blood Concentration in a Kidney Transplant Recipient
- Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers
- Evaluation of Calvert's Formula for Dosage Adjustment of Carboplatin in Japanese Patients with Hormone Refractory Prostate Cancer(Biopharmacy)
- Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer
- ラットにおけるペプチドトランスポータを介するβ-ラクタム抗生物質セフチブテンの吸収に及ぼす亜鉛の阻害効果
- Temporal Decline in Sirolimus Elimination Immediately After Pancreatic Islet Transplantation
- Delayed Effect of Grapefruit Juice on Pharmacokinetics and Pharmacodynamics of Tacrolimus in a Living-Donor Liver Transplant Recipient
- 腎上皮細胞におけるクレアチニンの経細胞輸送
- Required Transient Dose Escalation of Tacrolimus in Living-Donor Liver Transplant Recipients with High Concentrations of a Minor Metabolite M-II in Bile
- Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5